Literature DB >> 23023095

Extrapyramidal signs by dementia severity in Alzheimer disease and dementia with Lewy bodies.

Berneet Kaur1, Danielle J Harvey, Charles S Decarli, Lin Zhang, Marwan N Sabbagh, John M Olichney.   

Abstract

Alzheimer disease (AD) and dementia with Lewy bodies (DLB) are common etiologies of dementia with overlapping clinical features. Our objective was to determine which extrapyramidal signs (EPSs) are most helpful in identifying DLB. We analyzed data from the National Alzheimer's Coordinating Center, including demographics, Unified Parkinson's Disease Rating Scale (UPDRS) scores, Mini-Mental State Examination (MMSE) scores, and clinical diagnosis. The subjects were divided into 3 groups: AD, DLB, or Lewy body variant (LBV). The UPDRS motor scores were totaled and analyzed within and across the MMSE strata using regression techniques. Further, we divided UPDRS subscores into 9 EPSs, dichotomized as either present or absent. Logistic regression analysis was used to compare each of the EPS in the AD and Lewy body (DLB+LBV) groups. DLB subjects (n=130) were more likely to be male individuals, younger, and have higher MMSE scores (P<0.001) compared with that in AD (n=1826) or LBV (n=105) subjects. Differences were found for total UPDRS score and number of EPSs (P<0.001), after controlling for age, sex, and MMSE. Logistic regression models demonstrated that masked facies best differentiated AD from Lewy body (odds ratio=6.5, P<0.001, 95% confidence interval, 3.8-11.1). If these findings are neuropathologically validated, then the presence of specific EPS may help clinicians better differentiate AD and DLB.

Entities:  

Mesh:

Year:  2013        PMID: 23023095      PMCID: PMC3562426          DOI: 10.1097/WAD.0b013e31826f040d

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  33 in total

1.  Research evaluation and prospective diagnosis of dementia with Lewy bodies.

Authors:  Oscar L Lopez; James T Becker; Daniel I Kaufer; Ronald L Hamilton; Robert A Sweet; William Klunk; Steven T DeKosky
Journal:  Arch Neurol       Date:  2002-01

2.  Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

Authors:  Irene Hegeman Richard; Anne Wallace Justus; Nigel H Greig; Frederick Marshall; Roger Kurlan
Journal:  Clin Neuropharmacol       Date:  2002 Nov-Dec       Impact factor: 1.592

3.  Diagnostic accuracy of dementia with Lewy bodies.

Authors:  U Hohl; P Tiraboschi; L A Hansen; L J Thal; J Corey-Bloom
Journal:  Arch Neurol       Date:  2000-03

4.  Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

Authors:  I G McKeith; C G Ballard; R H Perry; P G Ince; J T O'Brien; D Neill; K Lowery; E Jaros; R Barber; P Thompson; A Swann; A F Fairbairn; E K Perry
Journal:  Neurology       Date:  2000-03-14       Impact factor: 9.910

5.  Ambulatory objective assessment of tremor in Parkinson's disease.

Authors:  J I Hoff; E A Wagemans; B J van Hilten
Journal:  Clin Neuropharmacol       Date:  2001 Sep-Oct       Impact factor: 1.592

Review 6.  Atypical antipsychotics in Parkinson-sensitive populations.

Authors:  Joseph H Friedman; Hubert H Fernandez
Journal:  J Geriatr Psychiatry Neurol       Date:  2002       Impact factor: 2.680

Review 7.  Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.

Authors:  B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

8.  Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies.

Authors:  A R Merdes; L A Hansen; D V Jeste; D Galasko; C R Hofstetter; G J Ho; L J Thal; J Corey-Bloom
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

9.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

10.  DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging.

Authors:  T J Ferman; G E Smith; B F Boeve; R J Ivnik; R C Petersen; D Knopman; N Graff-Radford; J Parisi; D W Dickson
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

View more
  5 in total

1.  Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition.

Authors:  Joanne M Hamilton; David P Salmon; Rema Raman; Lawrence A Hansen; Eliezer Masliah; Guerry M Peavy; Douglas Galasko
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

Review 2.  Lewy body disease or diseases with Lewy bodies?

Authors:  Kateřina Menšíková; Radoslav Matěj; Carlo Colosimo; Raymond Rosales; Lucie Tučková; Jiří Ehrmann; Dominik Hraboš; Kristýna Kolaříková; Radek Vodička; Radek Vrtěl; Martin Procházka; Martin Nevrlý; Michaela Kaiserová; Sandra Kurčová; Pavel Otruba; Petr Kaňovský
Journal:  NPJ Parkinsons Dis       Date:  2022-01-10

3.  Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer's disease.

Authors:  Yesica Gloria; Kelly Ceyzériat; Stergios Tsartsalis; Philippe Millet; Benjamin B Tournier
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

4.  Comparative Incidence of Conformational, Neurodegenerative Disorders.

Authors:  Jesús de Pedro-Cuesta; Alberto Rábano; Pablo Martínez-Martín; María Ruiz-Tovar; Enrique Alcalde-Cabero; Javier Almazán-Isla; Fuencisla Avellanal; Miguel Calero
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

5.  Apolipoprotein E e4 allele is associated with extrapyramidal symptoms in Alzheimer's disease.

Authors:  Yang-Pei Chang; Mei-Chuan Chou; Chiou-Lian Lai; I Chien; Yuan-Han Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-09       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.